MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

A cell-penetrating peptide (CPP) did not decrease 150-kDa BoNT/A toxin adsorption to surfaces or increase toxin potency or duration in a prototype formulation

D. Rupp, G. Nicholson, R. Briode, C. Nino, M. Do, J. Wan, L. Le, E. Vazquez-Cintron, C. Wu, M. Nelson, L. Steward, MF. Brin, A. Brideau-Andersen (Irvine, USA)

Meeting: MDS Virtual Congress 2021

Abstract Number: 291

Keywords: Botulinum toxin: Chemical subtypes

Category: Neuropharmacology

Objective: To examine the effect of a cell-penetrating peptide (CPP) in a prototype formulation using toxin adsorption, in vivo potency, and duration analyses.

Background: Unit potencies of botulinum neurotoxin type A (BoNT/A) drugs are not interchangeable due in part to unique drug formulations and manufacturing processes. Various excipients are used to stabilize BoNT/A and prevent adsorption to surfaces.

Method: Size-exclusion chromatography compared adsorption of 150-kDa BoNT/A toxin formulated in either potassium phosphate/NaCl buffer containing polysorbate 20, 23.5 µg/mL CPP (synthesized sequence: RKKRRQRRRG-[K]15-GRKKRRQRRR) with and without polysorbate 20, human serum albumin (HSA), or in buffer alone. Digit abduction score (DAS) testing compared the potency and duration of 150-kDa BoNT/A toxin at an approximate ED50 dose formulated in histidine buffer/trehalose buffer containing polysorbate 20, 0.235 µg CPP/unit BoNT/A with or without polysorbate 20, or in bovine serum albumin (BSA)/0.9% NaCl.

Results: Toxin adsorption to glass surface occurred in buffer control and CPP-only solutions at 7 hours; toxin recoveries were <64%. At 14 and 21 hours, buffer control and CPP-alone samples had decreased toxin recoveries of <42%; samples containing polysorbate 20 or HSA maintained toxin recoveries of >95%. In the mouse DAS assay, BoNT/A prepared in polysorbate formulations with or without CPP exhibited similar, predictive DAS efficacy (>ED50) and duration versus formulation in BSA/0.9% NaCl. In contrast, the formulation in CPP alone demonstrated decreased potency (<<ED25) and duration. Results from rat DAS assay showed similar trends.

Conclusion: CPP inclusion in a BoNT/A formulation neither prevents toxin adsorption nor increases potency or duration.

To cite this abstract in AMA style:

D. Rupp, G. Nicholson, R. Briode, C. Nino, M. Do, J. Wan, L. Le, E. Vazquez-Cintron, C. Wu, M. Nelson, L. Steward, MF. Brin, A. Brideau-Andersen. A cell-penetrating peptide (CPP) did not decrease 150-kDa BoNT/A toxin adsorption to surfaces or increase toxin potency or duration in a prototype formulation [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/a-cell-penetrating-peptide-cpp-did-not-decrease-150-kda-bont-a-toxin-adsorption-to-surfaces-or-increase-toxin-potency-or-duration-in-a-prototype-formulation/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to MDS Virtual Congress 2021

MDS Abstracts - https://www.mdsabstracts.org/abstract/a-cell-penetrating-peptide-cpp-did-not-decrease-150-kda-bont-a-toxin-adsorption-to-surfaces-or-increase-toxin-potency-or-duration-in-a-prototype-formulation/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley